You are here

Article Text

Article menu
Download PDFPDF
DTB Select
Renewed safety warnings for yellow fever vaccine

https://doi.org/10.1136/dtb.2019.000057

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Review of: Medicines and Healthcare products Regulatory Agency. Yellow fever vaccine (Stamaril) and fatal adverse reactions: extreme caution needed in people who may be immunosuppressed and those 60 years and older. Drug Safety Update 2019;12:1.

    Key learning points

    • Two cases of fatal adverse reactions following immunisation with yellow fever vaccine have prompted the Medicines and Healthcare products Regulatory Agency to issue a safety update.

    • Yellow fever vaccine must not be administered to anyone with a medical history of thymus dysfunction or who is immunosuppressed.

    • Extreme caution must be used, and a careful risk assessment conducted, before administering yellow fever vaccine to people aged 60 years and older.

    Healthcare professionals are reminded that yellow fever vaccine must not be given to people who may be immunosuppressed, those with a history of …

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.